Evidence map›Paper›PMID 33457076›Full record

ArticleOncoimmunology2020

Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.

Ryusuke Hayashi, Toshihiro Nagato, Takumi Kumai, Kenzo Ohara, Mizuho Ohara, Takayuki Ohkuri, Yui Hirata-Nozaki, Shohei Harabuchi, Akemi Kosaka, Marino Nagata and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 2 countries.

Ryusuke HayashiDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Toshihiro NagatoDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.ORCID 0000-0001-8326-8296
Takumi KumaiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Kenzo OharaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Mizuho OharaDepartment of Surgery, Asahikawa Medical University, Asahikawa, Japan.
Takayuki OhkuriDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Yui Hirata-NozakiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Shohei HarabuchiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Akemi KosakaDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Marino NagataDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Yuki YajimaDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Syunsuke YasudaDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Kensuke OikawaDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Michihisa KonoDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Kan KishibeDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Miki TakaharaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Akihiro KatadaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Tatsuya HayashiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Esteban CelisCancer Immunology, Inflammation and Tolerance Program, Augusta University, Georgia Cancer Center, Augusta, GA, USA.
Yasuaki HarabuchiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Hiroya KobayashiDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Asahikawa Medical University · JPAugusta University Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Placenta-specific 1 (PLAC1) is expressed primarily in placental trophoblasts but not in normal tissues and is a targetable candidate for cancer immunotherapy because it is a cancer testis antigen known to be up-regulated in various tumors. Although peptide epitopes capable of stimulating CD8 T cells have been previously described, there have been no reports of PLAC1 CD4 helper T lymphocyte (HTL) epitopes and the expression of this antigen in head and neck squamous cell carcinoma (HNSCC). Here, we show that PLAC1 is highly expressed in 74.5% of oropharyngeal and 51.9% of oral cavity tumors from HNSCC patients and in several HNSCC established cell lines. We also identified an HTL peptide epitope (PLAC1

Indexed as

Head and Neck NeoplasmsPregnancy ProteinsAntigens, NeoplasmEpitopes, T-LymphocyteFemaleHumansMalePlacentaPregnancySquamous Cell Carcinoma of Head and NeckT-Lymphocytes, Helper-InducerAntigens, NeoplasmEpitopes, T-LymphocytePLAC1 protein, humanPregnancy ProteinsCD4 T cellsepitopehead and neck squamous cell carcinomahelper T lymphocytesimmunotherapypeptide vaccinePLAC1Placenta-specific 1

Identifiers

PMID33457076
PMCPMC7781841
OpenAlexW3115815038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.